Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Zhu, FC; Zhuang, CL; Chu, K; Zhang, L; Zhao, H; Huang, SJ; Su, YY; Lin, HY; Yang, CL; Jiang, HM; Zang, X; Liu, DL; Pan, HX; Hu, YM; Liu, XH; Chen, Q; Song, QQ; Quan, JL; Huang, ZH; Zhong, GH; Chen, JY; Han, JL; Sun, H; Cui, LB; Li, JX; Chen, YX; Zhang, TY; Ye, XZ; Li, CG; Wu, T; Zhang, J; Xia, NS
Zhu, FC (通讯作者)，Jiangsu Prov Ctr Dis Control & Prevent, Publ Hlth Res Inst Jiangsu Prov, Nanjing 210000, Jiangsu, Peoples R China.;Xia, NS (通讯作者)，Xiamen Univ, Sch Publ Hlth,State Key Lab Mol Vaccinol & Mol Di, Chinese Acad Med Sci,Natl Inst Diagnost & Vaccine, Res Unit Frontier Technol Struct Vaccinol,Collabo, Xiamen 361102, Fujian, Peoples R China.
LANCET RESPIRATORY MEDICINE, 2022; 10 (8): 749
